Potential roles of cell-derived microparticles in ischemic brain disease

Neurological Research

Volumn 31, Issue 8, 2009, Pages 799-806

  Horstman, Lawrence L ^a   Jy, Wenche ^a   Bidot, Carlos J ^a   Nordberg, Mary L ^b   Minagar, Alireza ^b   Alexander, J Steven ^c   Kelley, Roger E ^b   Ahn, Yeon S ^a,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d NONE   (United States)

Author keywords

Endothelial microparticles; Endothelium; Ischema; Platelet; Stroke

Indexed keywords

ARACHIDONIC ACID; DIACYLGLYCEROL; DIGOXIN; GINKGOLIDE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LEUKOTRIENE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; PROSTAGLANDIN; PROTEIN C; SPHINGOLIPID; THROMBOCYTE ACTIVATING FACTOR; THROMBOPLASTIN; THROMBOXANE A2;

ALZHEIMER DISEASE; ANGIOPLASTY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BRAIN ISCHEMIA; COGNITIVE DEFECT; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIUM CELL; ERYTHROCYTE; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HUMAN; INFLAMMATION; KIDNEY CELL; LEUKOCYTE; MEDLINE; MEMBRANE MICROPARTICLE; MICROVASCULAR ISCHEMIA; MONOCYTE; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; REVIEW; SYNAPSE VESICLE; THROMBOCYTE; THROMBOCYTOPENIC PURPURA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ALZHEIMER DISEASE; ANIMALS; ANTIPHOSPHOLIPID SYNDROME; ATRIAL FIBRILLATION; BRAIN; BRAIN ISCHEMIA; CELL-DERIVED MICROPARTICLES; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; HUMANS; INTRACRANIAL THROMBOSIS; MODELS, NEUROLOGICAL; MULTIPLE SCLEROSIS;

EID: 69249127810     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164109X12445505689526     Document Type: Review

References (127)

1. Piccin A, Murphy WG, Smith OP. Circulating microparticles: Pathophysiology and clinical implications. Blood Rev 2007; 21: 157-171 (Pubitemid 46529055)
2. Horstman LL, Ahn YS. Platelet microparticles: A wide-angle perspective. Crit Rev Oncol/Hematol 1999; 30: 111-142
3. Horstman LL, Jy W, Jimenez JJ, et al. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9: 1118-1135
4. Horstman LL, Minagar A, Jy W, et al. Cell-derived microparticles and exosomes in neuroinflammatory conditions. Int Rev Neurobiol 2007; 79: 229-268
5. Engelmann B, Luther T, Muller I. Intravascular tissue factor pathway - a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003; 89: 3-8 (Pubitemid 36149785)
6. Giesen PLA, Nemerson Y. Tissue factor on the loose. Sem Thomb Haemost 2000; 26: 379-383
7. Iwamoto S, Kawasaki T, Kambayashi J, et al. Platelet microparticles: A carrier of platelet-activating factor? Biochem Biophys Res Commun 1996; 218: 940-944
8. Siddiqui FA, Desai H, Amirkhosravi A, et al. The presence and release of tissue factor from human platelets. Platelets 2002; 13: 247-253 (Pubitemid 34787736)
9. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2002; 100: 45a Ab 157
10. Satta N, Toti F, Feugeas O, et al. Monocyte vesiculation as a possible mechanism of dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 153: 3245-3255 (Pubitemid 24292551)
11. Kagawa H, Komiyama Y, Nakamura S, et al. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. Thromb Res 1998; 91: 297-304 (Pubitemid 28454727)
12. Biro E, Sturk-Maquelin N, Vogel GMT, et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1: 2561-2568
13. Chou J, Mackman N, Skoloff GM, et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-3197 (Pubitemid 39507134)
14. Steppich B, Mattisek C, Sobczyk D, et al. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. Thromb Haemost 2005; 93: 35-39 (Pubitemid 40124252)
15. Hron G, Kollars M, Binder BR, et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402 (Pubitemid 44127523)
16. Bidot L, Jy W, Bidot C, Jr, et al. Microparticle-mediated thrombin generation assay: Enhanced activity in patients with recurrent thrombosis. J Thromb Haemost 2008; 6: 913-919 (Pubitemid 351689911)
17. Ahn YS. Cell-derived microparticles: 'Iniature envoys with many faces'. J Thromb Haemost 2005; 3: 884-887
18. Freyssinet JM. Cellular microparticles: What are they bad or good for? J Thromb Haemost 2003; 1: 1655-1662
19. Fourcade O, Simon M-F, Viode C, et al. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 1995; 80: 919-927
20. Barry OP, Pratico D, Lawson JA, et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-2127 (Pubitemid 27203768)
21. Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis 2006; 36: 182-187
22. Takamori, et al. Synaptic vesicles: an organelle comes of age. Cell 2006; 127: 831-846
23. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288
24. Jy W, Horstman LL, Arce M, et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119: 334-345
25. Ahn YS, Horstman LL, Jy W, et al. Vascular dementia in patients with immune thrombocytopenic purpura (ITP). Thromb Res 2002; 107: 337-344 (Pubitemid 36139888)
26. Zucker-Franklin D, Karpatkin S. Red cell and platelet fragmentation in idiopathic thrombocytopenic purpura. N Engl J Med 1977; 297: 517-523 (Pubitemid 8187085)
27. Lee YJ, Horstman LL, Janania J, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72: 295-304 (Pubitemid 23329372)
28. Brey RL, Levine SR, Stallworth CL. Neurologic manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The Antiphospholipid Syndrome II: Autoimmune Thrombosis, New York: Elsevier, 2002: pp. 155-168
29. Sanna G, Bertolaccini ML, Hughes GRV. Hughes syndrome, the antiphospholipid syndrome. A new chapter in neurology. Ann NY Acad Sci 2005; 1051: 465-486
30. Galli M, Bevers EM, Comfurius P, et al. Effects of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993; 83: 466-472 (Pubitemid 23080018)
31. Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: A potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91: 667-673 (Pubitemid 38477445)
32. Horstman LL, Jy W, Bidot CJ, et al. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation 2009; 6: 3
33. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600
34. Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost 1996; 75: 427-431 (Pubitemid 26099707)
35. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003; 123: 896-902 (Pubitemid 37533302)
36. Kelton JG, Warkentin TE, Hayward CPM, et al. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. Blood 1992; 80: 2246-2251
37. Koenig DW, Barley-Maloney L, Daniel TO. A western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies. J Clin Immunol 1993; 13: 204-211 (Pubitemid 23151225)
38. Rieger M, Mannucci PM, Hovinga JAK, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-1267 (Pubitemid 41129589)
39. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic hemolytic anemia and antiphospholipid antibodies. Ann Rheum Dis 2004; 63: 730-736 (Pubitemid 38658405)
40. Trent K, Neustater BR, Lottenberg R. Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: A report of two cases. Amer J Hematol 1997; 54: 155-159 (Pubitemid 27079423)
41. Zahir A, Costedoat-Chalumeau N, Veyradier A, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum 2004; 50: 3260-3264 (Pubitemid 39372003)
42. Nesher G, Hanna VE, Moore TL, et al. Thrombotic microangiopathic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994; 24: 165-172
43. Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28: 1-19 (Pubitemid 28378079)
44. Ren G, Hack BK, Cunningham PN, et al. A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells. Clin Immunol 2002; 103: 43-53 (Pubitemid 34478419)
45. Ruiz-Torres MP, Casiraghi F, Galbusera M, et al. Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93: 443-452 (Pubitemid 40392531)
46. Hamilton KK, Hattori R, Esmon CT, et al. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-3814 (Pubitemid 20096011)
47. Sims PJ, Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today 1991; 12: 338-341
48. Horstman LL, Jy W, Schultz DR, et al. Complement mediated fragmentation and lysis of opsonized platelets: Gender differences in sensitivity. J Lab Clin Med 1994; 123: 515-525
49. Barber PA, Hach S, Tippett LJ, et al. Cerebral ischemic lesions on diffusion-weighted imaging are associated with neurocognitive decline after cardiac surgery. Stroke 2008; 39: 1427-1433
50. Shaw PJ, Bates D, Cartlidge NEF, et al. Early neurological complications of coronary artery bypass surgery. Br Med J 1985; 291: 1384-1387 (Pubitemid 16212354)
51. Shaw PJ, Bates D, Cartlidge NEF, et al. Early intellectual dysfunction following coronary bypass surgery. Q J Med 1986; 58: 59-68 (Pubitemid 16101942)
52. Ahlgren E, Lundqvist A, Nordland A, et al. Neurocognitive impairment and driving performance after coronary artery bypass surgery. Eur J Cadiothorac Surg 2003; 23: 334-340 (Pubitemid 36298540)
53. Blumenthal JA, Madden DJ, Burker EJ, et al. A preliminary study of the effects of cardiac procedures on cognitive performance. Int J Psychosom 1991; 38: 13-16
54. Schroeder SA. The complications of coronary arteriography: A problem that won't go away. Am Heart J 1980; 99: 139-141
55. Thomas TD, Troost BT. Permanent cerebral blindness after cardiac catheterization. Cathet Cardiovasc Diagn 1989; 4: 228-230
56. Gemmell CH, Ramirez SM, Yeo EL, et al. Platelet activation in whole blood by artificial surface: Identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J Lab Clin Med 1995; 125: 276-287
57. Dewanjee MK, Kapadvanjwala M, Mao WW, et al. A higher blood flow window of reduced thrombogenicity and acceptable fragmentation in a hollow fiber hemodialyzer. ASAIO J 1993; 39: M363-M367 (Pubitemid 23311720)
58. Muriithi EW, Belcher PR, Rao JN, et al. The effects of heparin and extracorporeal circulation on platelet counts and platelet micro-aggregation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2000; 120: 538-543 (Pubitemid 30677372)
59. Rinder CS. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 107: 280-288 (Pubitemid 24050529)
60. Miyamoto S, Marcinkiewicz C, Edmunds LH, Jr, et al. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GP IIb/IIIa. Thromb Haemost 1998; 80: 225-230 (Pubitemid 28393613)
61. Nieuwland R, Berckmans RJ, Maquelin KN, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96: 3534-3541 (Pubitemid 27513430)
62. Sturk-Maquelin KN, Nieuland R, Romijn FP, et al. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003; 1: 1920-1926
63. Heemels MT. Neurodegeneration. Nature 2006; 443: 767-807
64. Kalaria RN. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002; 204: 29-34 (Pubitemid 35287372)
65. Kalaria RN. Vascular factors in Alzheimer's disease. Int Psychogeriatr 2003; 15: 47-52
66. Kalaria RN, Kenny RA, Ballard CG, et al. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 2004; 226: 75-80
67. Pluta R. Is the ischemic blood-brain barrier insufficiency responsible for full-blown Alzheimer's disease? Neurol Res 2006; 28: 665-671
68. Sevush S, Jy W, Horstman LL, et al. Platelet activation in Alzheimer's disease. Arch Neurol 1998; 55: 530-536
69. Jy W, Horstman LL, Park H, et al. Platelet aggregates as markers of platelet activation: Characterization of flow cytometric method suitable for clinical applications. Am J Hematol 1998; 57: 33-42 (Pubitemid 28047196)
70. Jy W, Mao WW, Horstman LL, et al. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis 1995; 21: 217-231 (Pubitemid 26083518)
71. DiLuca M, Pastorino L, Bianchetti A, et al. Differential level of platelet amyloid beta precursor protein isoforms. Arch Neurol 1998; 55: 1195-1200
72. Davies TA, Long HJ, Eisenhauer PB, et al. Beta amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: Usage of a novel blood brain barrier endothelial cell model system. Amyloid 2000; 7: 153-165
73. DiLuca M, Colciaghi F, Pastorino L, et al. Platelets as a peripheral district to study pathogenetic mechanisms of Alzheimer disease: The case of amyloid precursor protein. Eur J Pharmacol 2000; 405: 277-283 (Pubitemid 30734186)
74. Borroni B, Colciaghi F, Pastorino L, et al. Amyloid precursor protein in platelets of patients with Alzheimer disease: Effect of acetylcholinesterase inhibitor treatment. Arch Neurol 2001; 58: 442-446 (Pubitemid 32217461)
75. Nomura S, Komiyama Y, Miyake T, et al. Amyloid beta-protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost 1994; 72: 519-522 (Pubitemid 24305642)
76. Simak J, Holada K, D'Agnillo F, et al. Cellular prion protein is expressed on endothelial cells and is released during apoptosis on membrane microparticles found in human plasma. Transfusion 2002; 42: 334-342
77. Wyss-Coray T, Mucke L. Ibuprofen, inflammation and Alzheimer disease. Nat Med 2000; 6: 973-974
78. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: Beyond strictly antiplatelet actions. Blood 2007; 109: 2285-2292 (Pubitemid 46425865)
79. LeBars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Gingko biloba for dementia. N Engl J Med 1997; 278: 1327-1332 (Pubitemid 27449692)
80. Braquet P. The ginkgolides: Potent platelet-activating factor antagonists isolated from Ginkgo biloba L.: Chemistry, pharmacology and clinical applications. Drugs Future 1987; 12: 643-699
81. Braquet P, Touqui L, Shen TY, et al. Perspectives in platelet activating factor research. Pharm Rev 1987; 39: 97-145 (Pubitemid 17105406)
82. James-Krack MR, Sexe RB, Shukla SD. Picomolar platelet activating factor mobilizes Ca to change platelet shape without activating phopholipase C or protein kinase C: Simultaneous fluorometric measurements of intracellular free Ca concentration and aggregation. J Pharm Exper Ther 1994; 271: 824-831
83. Lindsberg PJ, Hallenbeck JM, Feuerstein G. Platelet activating factor in stroke and brain injury. Ann Neurol 1991; 30: 117-129
84. Mitsios JV, Vini MP, Stengel D, et al. Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler Thromb Vasc Biol 2006; 26: 1907-1913 (Pubitemid 44305349)
85. Dutta-Roy AK, Gordon MJ, Kelly C, et al. Inhibitory effect of Ginkgo biloba extract on human platelet aggregation. Platelets 1999; 10: 298-305 (Pubitemid 29490856)
86. Yagmur E, Piatskowski A, Groger A, et al. Bleeding complications under Gingko biloba medication. Am J Hematol 2005; 79: 343-345 (Pubitemid 41098855)
87. Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma 377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007; 204: 571-582 (Pubitemid 46457080)
88. Adams RA, Schachtrup C, Davalos D, et al. Fibringogen signal transduction as a mediator and therapeutic target in inflammation: Lessons from multiple sclerosis. Curr Med Chem 2007; 14: 2925-2936 (Pubitemid 350201659)
89. Han MH, Hwang SU, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-1080
90. Vallar L, Regnault V, Latger-Cannard V, et al. Beta 2-glycoprotein 1 binding to platelet microparticle membrane specifically reduces immunoreactivity of glycoproteins IIb/IIIa. Thromb Haemost 2001; 85: 314-319 (Pubitemid 32140578)
91. Perez-Casal M, Downey C, Fukudome K, et al. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 2005; 105: 1515-1522 (Pubitemid 40223668)
92. Minagar A, Jy W, Jimenez JJ, et al. Multiple sclerosis as a vascular disease. Neurol Res 2006; 28: 230-235
93. Minagar A, Jy W, Jimenez JJ, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001; 56: 1319-1324 (Pubitemid 32455291)
94. Bidot CJ, Horstman LL, Jy W, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis. BMC Neurol 2007; 7: 36-42 (Pubitemid 351201644)
95. Barber M, Tait RC, Scott J, et al. Dementia in subjects with atrial fibrillation: Hemostatic function and the role of anticoagulation. J Thromb Haemost 2004; 2: 1873-1878. (Pubitemid 40192736)
96. Chirinos JA, Castrellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with non-valvular atrial fibrillation. Heart Rhythm 2005; 2: 525-529 (Pubitemid 40521368)
97. Ahn YS, Jy W, Horstman LL, et al. Cell-derived microparticles: A mediator of inflammation in aortic valve stenosis?. Thromb Haemost 2008; 99: 657-658 (Pubitemid 351694220)
98. O'Connell DJ, Rozenvayn N, Flaumenhaft R. Phosphatidylinositol 4,5-bisphosphate regulates activation-induced platelet microparticle formation. Biochemistry 2005; 44: 6361-6370 (Pubitemid 40570730)
99. Abid-Hussein MN, Boing AN, Sturk A, et al. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost 2007; 98: 1096-1107 (Pubitemid 350107696)
100. Perler BA. Should statins be given routinely before carotid endarterectomy? Perspect Vasc Surg Endovasc Ther 2007; 19: 240-245
101. Tramontano AF, O'Leary J, Black AD, et al. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: Implication for the Rho-kinase pathway. Biochem Biophys Res Commun 2004; 320: 34-38 (Pubitemid 38781781)
102. Rychly J, Nebe B. Therapeutic strategies in autoimmune disease by interfering with leukocyte endothelium interaction. Curr Pharm Des 2006; 12: 3799-3806 (Pubitemid 44560713)
103. Fukushima S, Coppen SR, Varela-Carver A, et al. A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1 via retrograde intracoronary route. Circulation 2006; 114 (Suppl. I): 251-256 (Pubitemid 44297159)
104. Nakamura K, Honda K, Mizutani T, et al. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12: 4628-4635 (Pubitemid 44269718)
105. Kieseier BC, Wiendl M, Hemmer B, et al. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 2007; 20: 286-293
106. Falati S, Lin Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependant upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-1598 (Pubitemid 36682554)
107. Jimenez JJ, Jy W, Mauro L, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109: 175-180 (Pubitemid 36712905)
108. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-366 (Pubitemid 26097120)
109. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissues and donors. Annu Rev Immunol 2000; 18: 813-827 (Pubitemid 30365398)
110. Sim D, Flaumenhaft R, Furie B, et al. Interactions of platelets, blood-borne tissue factor, and fibrin during arteriolar thrombus formation in vivo. Microcirculation 2005; 12: 301-311 (Pubitemid 40691825)
111. Gross PL, Furie BC, Merrill-Skoloff G, et al. Leukocyte- versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol 2005; 78: 1318-1326 (Pubitemid 41779238)
112. Jimenez JJ, Jy W, Mauro L, et al. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult Scler 2005; 11: 310-315 (Pubitemid 40775188)
113. Mack M, Kleinschmidt A, Bruhl H, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-dervied microparticles: A mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 2000; 6: 769-775 (Pubitemid 30469425)
114. Fritzsching B, Schwer B, Kartenbeck J, et al. Release and intercellular transfer of cell surface CD81 via microparticles. J Immunol 2002; 169: 5531-5537 (Pubitemid 35291651)
115. Breimo ES, Østerud B. Generation of tissue factor-rich microparticles in an ex vivo whole blood model. Blood Coagul Fibrinolysis 2005; 16: 399-405
116. Scholz T, Temmler U, Krause S, et al. Transfer of tissue factor from platelets to monocytes: Role of platelet-derived microvesicles and CD62P. Thromb Haemost 2002; 88: 1033-1038 (Pubitemid 36018792)
117. Mause SF, von Hundelshausen P, Zernecke A, et al. Platelet microparticles, a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscl Thromb Vasc Biol 2005; 25: 1512-1518 (Pubitemid 40923377)
118. Rozmyslowicz T, Majka M, Kijowski J, et al. Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 2003; 17: 33-42 (Pubitemid 36106296)
119. Hussein MNA, Nieuwland R, Hau CM, et al. Cell-derived microparticles contain caspase-3 in vitro and in vivo. J Thromb Haemost 2005; 3: 888-896 (Pubitemid 41632816)
120. Pascual M, Lutz HU, Steiger G, et al. Release of vesicles enriched in complement receptor 1 from human erythrocytes. J Immunol 1993; 151: 397-404 (Pubitemid 23207005)
121. Broze GJ, Girard TJ, Novotny WF. The lipoprotein associated coagulation inhibitor. Prog Hemost Thromb 1991; 10: 243-268
122. Hansen JB, Huseby NE, Sandset PM, et al. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-229
123. Tselepsis AD, Dentan C, Karabina SAP, et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Arterioscler Thromb Vasc Biol 1995; 15: 1764-1773
124. Nomura S, Yanabu M, Miyake T, et al. Relationship of microparticles with beta2-glycoprotein I and P-selectin positivity to anticardiolipin antibodies in immune thrombocytopenic purpura. Ann Hematol 1995; 70: 25-30
125. Polz E, Wurm H, Kostner GM. Investigations on β2-glycoprotein in the rat: Isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980; 11: 265-270
126. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Prog Lipid Res 1991; 30: 105-138
127. McNally T, Mackie IJ, Isenberg DA, et al. β2 glycoprotein-1 inhibits factor XII activation on triglyceride rich lipoproteins: The effect of antibodies from plasma of patients with antiphospholipid syndrome. Thromb Haemost 1996; 76: 220-225 (Pubitemid 26285255)